Healthy Sleep
Also known as: Sleep Hygiene
Methodology & AI Transparency ⓘ
Healthy Sleep Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is sleep? While you are sleeping your brain and body functions are still active.
- 2 Real-world patient consensus: Diagnostic registry G47.6: Healthy Sleep is managed within Sleep Disorders (aka Sleep Hygiene).
- 3 Typical cash cost range: Differential triage of Healthy Sleep (G47.6) utilizes CBT-I behavioral sleep in Healthy Sleep (G47.6: efficiency tracking).
- 4 Top reported side effects / signs: Longitudinal Healthy Sleep monitoring tracks Insomnia Severity Index in Healthy Sleep (G47.6: (ISI)) toward < 7 (G47.6).
Ask our AI Specialists anything about Healthy Sleep
What Is Healthy Sleep?
What is sleep? While you are sleeping your brain and body functions are still active. Sleep is a natural process that helps your body restore energy, supports learning and memory, and keeps you healthy. During sleep, your brain cycles through different stages of non-rapid eye movement (non-REM) sleep and rapid eye movement (REM) sleep. Non-REM sleep has three stages that range from light to deep sleep, while REM sleep is when most dreaming occurs. During each stage, your brain waves, breathing, heart rate, and body temperature change throughout the night. Certain phases of sleep help you: Feel rested and energetic the next day.
Pathophysiology, Underlying Causes & Clinical Presentation
In Healthy Sleep (G47.6), physiological disruption stems from fragmented slow-wave/REM sleep in Healthy Sleep (G47.6: architecture), Cross-referenced with NIH MeSH (Sleep Hygiene), informing Insomnia, Sleep Apnea & Sleep Health protocols that track Nocturnal Oxygen Saturation in Healthy Sleep (G47.6: (SpO2)) (>= 94% nadir > 90% (G47.6)).
Common Symptoms & Clinical Signs
- • Feel rested and energetic the next day
- • Learn new information, get insight, and form memories
- • Presentation of Healthy Sleep (G47.6): unrefreshing morning waking in Healthy Sleep (G47.6: despite adequate hours)
- • Secondary Healthy Sleep clinical sign: loud habitual snoring, in Healthy Sleep (G47.6: witnessed breathing pauses,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Healthy Sleep Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Insomnia Severity Index in Healthy Sleep (G47.6: (ISI)) | < 7 (G47.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Healthy Sleep (G47.6: (SpO2)) | >= 94% nadir > 90% (G47.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Healthy Sleep (G47.6: Legs)) | > 75 ng/mL (G47.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Healthy Sleep
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ez Nite Sleep (Diphenhyramine Hydrochloride) Ez Nite Sleep • RxCUI 1049909-B41226613 | Histamine-1 Receptor Antagonist | 84% | $1.1600 | $ 92.02 /mo |
| Eszopiclone Lunesta • RxCUI 485442 | FDA Prescription Therapeutic Agent | 86% | $0.0871 | $ 12.03 /mo |
| Doxepin Adapin • RxCUI 966787 | Tricyclic Antidepressant | 84% | $1.3716 | $ 6.34 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Healthy Sleep)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus: What a 8,200-Participant Study Found TV P2-VP8 provided inferior protection against SRVGE compared to ROTARIX. Vaccine • 2026-01-05 • Phase III Randomized Trial | N = 8,200 | 96/100 | PMID 41319434 ↗ |
| New Insights on Immunogenicity and safety of concomitant vaccines given with 20-valent: What a 1,997-Participant Study Found Immune responses to routine children vaccines given with PCV20 were noninferior to those when given with PCV13. Vaccine • 2025-12-05 • Phase III Randomized Trial | N = 1,997 | 96/100 | PMID 41187484 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of: What a 1,001-Participant Study Found A 4-dose series of PVC20 was well tolerated and elicited robust serotype-specific immune responses expected to help protect infants and young children against pneumococcal disease due to the 20 vaccine serotypes. The Pediatric infectious disease journal • 2024-06-01 • Phase III Randomized Trial | N = 1,001 | 96/100 | PMID 38535409 ↗ |
| New Insights on Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal: What a 1,200-Participant Study Found Consistent with previous studies, a trend was observed toward lower pneumococcal OPA GMTs in the concomitant versus the non-concomitant group. Human vaccines & immunotherapeutics • 2022-12-31 • Phase III Randomized Trial | N = 1,200 | 96/100 | PMID 34726574 ↗ |
Healthy Sleep Patient Community & “People Like Me” Threads
Filter Healthy Sleep community threads and patient logs by age, biological sex, dosage, and treatment duration.